Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
TTHI's Cash to Debt is ranked higher than
90% of the 1248 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. TTHI: No Debt )
TTHI' s 10-Year Cash to Debt Range
Min: 4.13   Max: No Debt
Current: No Debt

Interest Coverage No Debt
TTHI's Interest Coverage is ranked higher than
75% of the 577 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. TTHI: No Debt )
TTHI' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 2
Z-Score: 9.86
M-Score: -4.62
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -73.13
TTHI's ROE (%) is ranked higher than
63% of the 1143 Companies
in the Global Biotechnology industry.

( Industry Median: -35.75 vs. TTHI: -73.13 )
TTHI' s 10-Year ROE (%) Range
Min: -67.28   Max: 37.41
Current: -73.13

-67.28
37.41
ROA (%) -63.33
TTHI's ROA (%) is ranked higher than
60% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: -28.24 vs. TTHI: -63.33 )
TTHI' s 10-Year ROA (%) Range
Min: -47.14   Max: 27.8
Current: -63.33

-47.14
27.8
ROC (Joel Greenblatt) (%) -23422.89
TTHI's ROC (Joel Greenblatt) (%) is ranked higher than
51% of the 1223 Companies
in the Global Biotechnology industry.

( Industry Median: -438.40 vs. TTHI: -23422.89 )
TTHI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -13626.3   Max: 1900.07
Current: -23422.89

-13626.3
1900.07
Revenue Growth (3Y)(%) -100.00
TTHI's Revenue Growth (3Y)(%) is ranked higher than
52% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. TTHI: -100.00 )
TTHI' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 163.5
Current: -100

0
163.5
EPS Growth (3Y)(%) 42.30
TTHI's EPS Growth (3Y)(%) is ranked higher than
95% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. TTHI: 42.30 )
TTHI' s 10-Year EPS Growth (3Y)(%) Range
Min: -100   Max: 51.8
Current: 42.3

-100
51.8
» TTHI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

TTHI Guru Trades in Q4 2013

Jim Simons 119,800 sh (+65.47%)
» More
Q1 2014

TTHI Guru Trades in Q1 2014

Jim Simons 131,100 sh (+9.43%)
» More
Q2 2014

TTHI Guru Trades in Q2 2014

Jim Simons 131,300 sh (+0.15%)
» More
Q3 2014

TTHI Guru Trades in Q3 2014

Jim Simons 149,700 sh (+14.01%)
» More
» Details

Insider Trades

Latest Guru Trades with TTHI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 6.25
TTHI's P/B is ranked higher than
73% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 6.13 vs. TTHI: 6.25 )
TTHI' s 10-Year P/B Range
Min: 0.9   Max: 7.53
Current: 6.25

0.9
7.53
EV-to-EBIT -6.07
TTHI's EV-to-EBIT is ranked higher than
75% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. TTHI: -6.07 )
TTHI' s 10-Year EV-to-EBIT Range
Min: -89.7   Max: 7.2
Current: -6.07

-89.7
7.2
Current Ratio 7.58
TTHI's Current Ratio is ranked higher than
83% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.74 vs. TTHI: 7.58 )
TTHI' s 10-Year Current Ratio Range
Min: 2.24   Max: 30.83
Current: 7.58

2.24
30.83
Quick Ratio 7.58
TTHI's Quick Ratio is ranked higher than
83% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. TTHI: 7.58 )
TTHI' s 10-Year Quick Ratio Range
Min: 1.66   Max: 30.83
Current: 7.58

1.66
30.83

Valuation & Return

vs
industry
vs
history
Price/Net Cash 7.80
TTHI's Price/Net Cash is ranked higher than
85% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 50.00 vs. TTHI: 7.80 )
TTHI' s 10-Year Price/Net Cash Range
Min: 2.13   Max: 64
Current: 7.8

2.13
64
Price/Net Current Asset Value 7.71
TTHI's Price/Net Current Asset Value is ranked higher than
84% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 29.38 vs. TTHI: 7.71 )
TTHI' s 10-Year Price/Net Current Asset Value Range
Min: 1.7   Max: 53.33
Current: 7.71

1.7
53.33
Price/Tangible Book 7.64
TTHI's Price/Tangible Book is ranked higher than
76% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9.38 vs. TTHI: 7.64 )
TTHI' s 10-Year Price/Tangible Book Range
Min: 1.52   Max: 38.25
Current: 7.64

1.52
38.25
Earnings Yield (Greenblatt) -16.50
TTHI's Earnings Yield (Greenblatt) is ranked higher than
60% of the 1218 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. TTHI: -16.50 )
TTHI' s 10-Year Earnings Yield (Greenblatt) Range
Min: 13.9   Max: 116.4
Current: -16.5

13.9
116.4

Analyst Estimate


Warning: Invalid argument supplied for foreach() in /home/gurufocu/public_html/modules/stock/estimate.php on line 31
Jun15 Jun16 Jun17
Revenue(Mil)
EPS($) -0.55 -0.26 0.14
EPS without NRI($) -0.55 -0.26 0.14

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:TTH.Canada, RFYA.Germany,
Transition Therapeutics Inc was incorporated on July 6, 1998 as 'Transition Therapeutics and Diagnostics Inc.' The Corporation filed articles of amendment on October 12, 2000 and on October 19, 2000 to create a class of non-voting shares (the 'Class B Shares') and to amend certain attributes of its Common Shares. On November 2, 2000, the Corporation filed articles of amendment to delete its private company restrictions. On December 14, 2000, the Corporation filed articles of amendment to change its name to 'Transition Therapeutics Inc.' The Company is a product-focused biopharmaceutical company developing novel therapeutics for disease indications with markets. The Company's technologies are focused on the treatment of Alzheimer's disease and diabetes. The Corporation operates in one business segment; that is the research and development of therapeutic agents. Its technologies in development include ELND005 (AZD-103) for the treatment of Alzheimer's disease; TT-301 and TT-302 which may have a therapeutic effect on diseases including arthritis, Alzheimer's disease, traumatic brain injury, intracerebral haemorrhage, and others, and TT401/402 for the treatment of diabetes. On July 15, 2011, the Company announced that ELND005 Phase 2 clinical trial data would be presented at the International Conference of Alzheimer's Disease (ICAD) meeting on July 18, 2011. Elan and Transition intend to share further detail regarding the Phase 2 data in a peer-reviewed publication.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK